Aurélien Marabelle
 | Aurélien Marabelle, MD, PhD, is the Clinical Director of the Cancer Immunotherapy Program at Gustave Roussy Cancer Center in Villejuif, France. Dr Marabelle’s clinical practice is dedicated to early phase Clinical trials in Cancer Immunotherapy and his translational research is focused on mechanisms of action of immune checkpoint monoclonal antibodies. He works as a senior medical oncologist and an investigator in the Drug Development Department (DITEP). He is coordinating a team focused on cancer immunotherapy translational research projects at INSERM. |
Diane Mathis
 | Dr. Mathis is currently a professor of Microbiology and Immunobiology at Harvard Medical School and holder of the Morton Grove-Rasmussen chair of Immunohematology. Dr. Diane Mathis obtained a BSc from Wake Forest University and a Ph.D. from the University of Rochester. She performed postdoctoral studies at the Laboratoire de Génétique Moléculaire des Eucaryotes in Strasbourg, France and at Stanford University Medical Center. Dr Mathis returned to France at the end of 1983, establishing a laboratory in conjunction with Christophe Benoist at the Institut de Genetique et de Biologie Moleculaire et Cellulaire in Strasbourg. The lab joined the Harvard Medical School Pathology department in spring 2009. Dr Mathis was elected to the National Academy of Sciences in 2003; the German Academy, Leupoldina, in 2007; and the American Acadamy of Arts and Sciences in 2012. Dr. Mathis is also an active member of the Commitee on Immunology at Harvard Medical School, the Broad Institute, the Dana Farber/Harvard Cancer Center and the Harvard Stem Cell Institute. |
Miriam Merad
 | Miriam Merad, MD, PhD, is the Mount Sinai Chair professor in Cancer Immunology and the Director of the Precision Immunology Institute at Mount Sinai School of Medicine in New York (NY, USA). Dr. Merad’s laboratory studies the contribution of macrophages and dendritic cells to Cancer and Inflammatory diseases in mice and humans. She has shown that tissue macrophages have unique functional attributes that contribute to tumor outcome and response to treatment. Dr. Merad pioneered mapping the regulatory network of dendritic cells (DCs) resulting in the identification of a lineage of DC, the CD103+ DC, that is now considered to be a key target to improve antiviral and antitumor immunity. Dr. Merad receives generous funding from the National Institutes of Health (NIH) for her research on innate immunity and their contribution to human disease and belongs to several NIH consortia. |
Katy Rezvani
 | Dr. Rezvani is Professor of Medicine, Director of Translational Research, Medical Director of the MD Anderson GMP and Cell Therapy Laboratory and Chief, Section of Cellular Therapy, Department of Stem Cell Transplant and Cellular Therapy, MD Anderson Cancer Center. Dr. Rezvani joined the faculty at the MDACC in 2012 from the Hammersmith Hospital in London, where she was Director of the allogeneic adult stem cell transplant program, Medical Director of the GMP facility and Director of the Transplant Immunology Research Laboratory. Dr. Rezvani has an active research laboratory program in transplantation immunology where the focus of her research group is to study the role of natural killer cells (NK) cells in mediating immunity against leukemia, and to understand the mechanisms of tumor-induced NK cell dysfunction. The goal of these studies is to develop strategies to enhance NK cell effector function against tumors by genetically engineering the cells to enhance their in vivo antileukemic activity and persistence. Her laboratory program in transplant immunology has led to the approval and funding of a number of Phase I/II studies of immunotherapy in patients with leukemia and lymphoma. |
Mario Sznol
 | Mario Sznol, MD, is Professor of Medicine, Leader, Melanoma/RCC Disease-Associated Research Team, and co-leader, Cancer Immunology Program at the Yale Cancer Center (New Haven, CT, USA). Recently, he was appointed the incoming President of the Society for Immunotherapy of Cancer (SITC). Dr. Sznol's interests include cancer immunotherapy, drug development for cancer, and treatment of patients with melanoma and renal cell carcinoma. After completing a fellowship in medical oncology at Mount Sinai College of Medicine in NYC in 1987, he joined the NCI as a Senior Investigator in the Investigational Drug Branch (IDB), Cancer Therapy Evaluation Program (CTEP). He was Head of the Biologics Evaluation Program, IDB, CTEP, from 1994-1999, and in 1999, was appointed Vice President of Clinical Development for Vion Pharmaceuticals in New Haven, CT. He joined the Yale faculty in medical oncology in 2004. |